 |
인쇄하기
취소
|
Baraclude and Viread to drive market growth in Korea
The domestic hepatitis B market is expected to witness significant changes as Yuhan’s Viread (tenofovir) is to be launched in the latter half of this year.
Currently, BMS’s Varaclude (entecavir) has led the domestic market with 90 billion won in sales last year, but Baraclude does not offer a paradigm change compared to Zeffix or Hepsera, the current antiviral standards of care, but does hav...
Currently, BMS’s Varaclude (entecavir) has led the domestic market with 90 billion won in sales last year, but Baraclude does not offer a paradigm change compared to Zeffix or Hepsera, the current antiviral standards of care, but does hav...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.